TARSUS PHARMACEUTICALS, INC. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- TARSUS PHARMACEUTICALS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $1.44M, a 30.61% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $1.10M, a 3.08% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-06-30 was $1.14M, a 144.30% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2023-06-30 was $465.00K, a 109.46% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $2.34M, a 30.19% increase from fiscal 2024.
- TARSUS PHARMACEUTICALS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $1.79M, a 82.23% increase from fiscal 2023.
- TARSUS PHARMACEUTICALS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $985.00K, a 113.20% increase from fiscal 2022.
- TARSUS PHARMACEUTICALS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $462.00K, a 109.05% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $1.44M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $2.34M 10-K · filed 2026-02-23 | |
| 2025-06-30 | $1.10M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $1.79M 10-K · filed 2026-02-23 | |
| 2024-06-30 | $1.14M 10-Q · filed 2025-11-04 | |
| 2023-12-31 | $985.00K 10-K · filed 2026-02-23 | |
| 2023-06-30 | $465.00K 10-Q · filed 2024-11-13 | |
| 2022-12-31 | $462.00K 10-K · filed 2025-02-25 | |
| 2022-06-30 | $222.00K 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $221.00K 10-K · filed 2023-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |